Relmada Therapeutics, Inc. RLMD Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance.
The official record: Relmada Therapeutics, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount?
- Relmada Therapeutics, Inc. (RLMD) reported effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount of $1.46M in Q4 2025.
- What does effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount mean?
- The change in the valuation allowance established against deferred tax assets, representing management's assessment of the likelihood that these assets will be realized. An increase in the allowance suggests uncertainty regarding the future utilization of tax benefits like net operating losses.